By Sriparna Roy and Bhanvi Satija (Reuters) -Shares of global vaccine makers were muted on Tuesday as investors and analysts ...

By Sriparna Roy and Bhanvi Satija (Reuters) -Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

Vaccine maker stocks are steady despite RFK Jr.'s decision to fire all members of the CDC expert panel on immunizations. Read ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...